These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29969644)

  • 1. Optimal platelet inhibition with cangrelor in comatose survivors of out-of-hospital cardiac arrest undergoing primary percutaneous coronary intervention.
    Fiore M; Gerbaud E; Coste P; Cetran L; Marchand H; Seguy B
    Resuscitation; 2018 Sep; 130():e1-e2. PubMed ID: 29969644
    [No Abstract]   [Full Text] [Related]  

  • 2. Ticagrelor Versus Clopidogrel in Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention and Hypothermia: A Randomized Study.
    Steblovnik K; Blinc A; Mijovski MB; Fister M; Mikuz U; Noc M
    Circulation; 2016 Dec; 134(25):2128-2130. PubMed ID: 27994027
    [No Abstract]   [Full Text] [Related]  

  • 3. Periprocedural platelet inhibition with cangrelor in P2Y
    Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
    Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).
    Cavender MA; Bhatt DL; Stone GW; White HD; Steg PG; Gibson CM; Hamm CW; Price MJ; Leonardi S; Prats J; Deliargyris EN; Mahaffey KW; Harrington RA;
    Circulation; 2016 Sep; 134(10):723-33. PubMed ID: 27482008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of both cangrelor and ticagrelor because of severe dyspnea during primary angioplasty.
    Di Filippo C; Caniato F; Cappelli F; Mattesini A; Meucci F; Sori A; Stolcova M; Agostini C; Bernardo P; Di Mario C
    J Cardiovasc Med (Hagerstown); 2021 Apr; 22(4):317-319. PubMed ID: 33633048
    [No Abstract]   [Full Text] [Related]  

  • 7. Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
    Mohammad MA; Andell P; Koul S; James S; Scherstén F; Götberg M; Erlinge D
    Platelets; 2017 Jun; 28(4):414-416. PubMed ID: 27885888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention.
    Badreldin HA; Carter D; Cook BM; Qamar A; Vaduganathan M; Bhatt DL
    Am J Cardiol; 2017 Aug; 120(3):359-361. PubMed ID: 28576266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effects during the transition between cangrelor and ticagrelor.
    Schneider DJ; Agarwal Z; Seecheran N; Keating FK; Gogo P
    JACC Cardiovasc Interv; 2014 Apr; 7(4):435-42. PubMed ID: 24656538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
    Gutierrez JA; Harrington RA; Blankenship JC; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Généreux P; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL;
    Eur Heart J; 2016 Apr; 37(14):1122-30. PubMed ID: 26400827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention.
    Price MJ
    Interv Cardiol Clin; 2017 Jan; 6(1):39-47. PubMed ID: 27886821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of TIcagrelor administered through a nasogastric tube to COMAtose patients undergoing acute percutaneous coronary intervention: the TICOMA study.
    Ratcovich H; Sadjadieh G; Andersson HB; Frydland M; Wiberg S; Dridi NP; Kjaergaard J; Holmvang L
    EuroIntervention; 2017 Feb; 12(14):1782-1788. PubMed ID: 28216475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cangrelor in Ticagrelor-Loaded STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
    Alexopoulos D; Pappas C; Sfantou D; Xanthopoulou I; Didagelos M; Kikas P; Ziakas A; Tziakas D; Karvounis H; Iliodromitis E
    J Am Coll Cardiol; 2018 Oct; 72(14):1750-1751. PubMed ID: 30261967
    [No Abstract]   [Full Text] [Related]  

  • 18. Practical considerations for cangrelor use in patients with acute coronary syndromes.
    Leonardi S; Bhatt DL
    Eur Heart J Acute Cardiovasc Care; 2019 Feb; 8(1):39-44. PubMed ID: 28574274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cangrelor: a review on pharmacology and clinical trial development.
    Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.